Xencor, Inc. (XNCR) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 1.82B USD. 52-week range 10.38 to 30.61 USD. Data as of 2026-10-09.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to ...